NCT01026389

Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease

Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 189 (actual)
• Sponsor: Guerbet · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.

Conditions

• Peripheral Arterial Disease

Interventions

Type	Name	Description
DRUG	Dotarem	DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
DRUG	Gadovist	Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-06-01
• Completion: 2012-01-01
• First posted: 2009-12-04
• Last updated: 2012-12-11
• Results posted: 2012-12-11

Locations

1 site across 1 country: Austria